The study is composed of two phases: Phase 1 and Phase 2. The purpose of the Phase 1 study is to test an investigational study drug (vaccine) called DPX-Survivac. In this study, the sponsor and investigators want to learn the safety profile of one dose level of study drug alone and two dose levels with cyclophospamide. In Phase 1 portion of this study, the safety profile and immune response following one cycle of 3 vaccinations will help the sponsor determine which dose level of the study drug with cyclophosphamide should be further investigated in the Phase 2 study. For Phase 1 portion, there are 10 study visits for a total of approximately 8 months in duration.
- Females age >= 18 years old of any racial or ethnic group
- Subjects with stage IIc-IV epithelial ovarian, fallopian tube, or peritoneal cancer who have completed adjuvant treatment consisting of up to 8 cycles of paclitaxel and carboplatin chemotherapy or other acceptable chemotherapy after initial debulking surgery with evidence of a complete or partial response by radiological imaging, are eligible
- Subjects with recurrent ovarian, fallopian tubal or peritoneal cancer who have clinical or radiologic evidence of complete or partial response or stable disease after completion of first-line chemotherapy for recurrent disease and are not suitable for additional cytotoxic therapy are eligible.
- Subjects undergoing concurrent chemotherapy, radiation therapy and immunotherapy are excluded.